Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen Raises $6.3M

NEW YORK (GenomeWeb) – Courtagen Life Sciences has raised about $6.3 million, the genetic testing firm disclosed in a document filed with the US Securities and Exchange Commission this week.

Courtagen did not disclose the identity of the investors or say how proceeds will be used. It did not respond to requests seeking clarification.

The Woburn, Mass.-based company develops tests for mitochondrial disorders, epilepsy and seizure disorders, Autism Spectrum Disorder, and other conditions based on next-generation sequencing technology. This week, it announced a deal with Seizure Tracker aimed at epilepsy.

In May it and Sciencewerke reached an agreement for the distribution of Courtagen's clinical NGS tests, and the month before that Courtagen and Connecticut Children's Medical Center said they would collaborate to identify alterations in genes associated with ASD.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.